- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Harlan Levine Previews Focus of Featured Discussion at Patient-Centered Oncology Care® 2020
During a featured discussion at this year’s Patient-Centered Oncology Care® 2020 virtual meeting, innovations and subsequent challenges in employing these advances within the treatment of cancer will be addressed.
During a featured discussion at this year’s Patient-Centered Oncology Care® 2020 virtual meeting, innovations and the subsequent challenges in employing these advances within the treatment of cancer will be addressed, said Harlan Levine, MD, president of strategy and business ventures at City of Hope.
Transcript
AJMC®: What message do you hope to bring to those taking part in Patient-Centered Oncology Care 2020?
Levine: I’m looking forward to the conference. My talk will focus on the fact that in 2020, we are making tremendous progress in the treatment of cancer, with new therapeutics and precision medicine changing the paradigm for care, but the speed with which these changes are happening and the cost of care are creating challenges—challenges for the well-intended community physicians that are trying to keep up with all the changes, but also challenges to affordability.
During my talk, I hope to show that cancer is different, and the methods that are traditionally used to manage both the quality and cost of chronic diseases such as diabetes or back pain should not be misapplied to cancer. In cancer, your best chance of cure is your first chance of cure, and during my talk, I hope to introduce new ideas and new approaches to make sure that people with cancer get the right care, at the right place, at the right time.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Frameworks for Advancing Health Equity: Trans and Gender Diverse Health Care
June 28th 2024Charlie Borowicz, manager of trans and gender diverse health at Allegheny Health Network, shares how the program offers comprehensive patient-first care to those in the LGBTQ+ and gender diverse community.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
